An editorial suggests that these findings make the case for targeted screening of standard CV disease risk factors in patients with severe or more active eczema and there may be a need to rethink thresholds for primary prevention interventions in this patient group, by factoring in severe eczema as an independent CV disease risk factor. It adds that the results may also have ramifications for allocation of healthcare resources in eczema; and prevention of CV disease by better control of severe eczema will contribute to the justification for expensive next generation biologic drugs that are becoming available for this disease. It concludes from these data that severe eczema has joined a growing list of chronic inflammatory conditions that may, in those with severe disease activity, contribute an independent increase in CV disease risk.